Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030401 | 0.87 | BRD4 (0.45) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL4359364 | 0.85 | PTGS2 (0.47) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL8430722 | 0.85 | PTGS2 (0.47) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL4352690 | 0.83 | POLB (0.49) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL1030028 | 0.81 | KDM4E (0.46) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL5809545 | 0.80 | PTGS2 (0.46) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL12402397 | 0.79 | PTGS2 (0.48) | PTGS2KCNJ6KCNJ5KCNJ3POLB | |
| SCHEMBL3322508 | 0.79 | LMNA (0.61) | PTGS2POLBKDM4EGAA | |
| SCHEMBL1030671 | 0.78 | RAB9A (0.50) | KCNJ6KCNJ5KCNJ3POLBSMYD3 | |
| SCHEMBL5109059 | 0.78 | POLB (0.41) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2021-08-17 | — | — | US | disclosed |
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2021-08-17 | — | — | US | disclosed |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8399472-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399472-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | PTGS2 615/4885KCNJ6 2793/4885KCNJ5 2208/4885 |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | SSB, HLA-DRB1, U2AF1 | PTGS2 2836/4885KCNJ6 2098/4885KCNJ5 1648/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | SSB, HLA-DRB1, U2AF1 | PTGS2 2836/4885KCNJ6 2098/4885KCNJ5 1648/4885 |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PTGS2 664/4885KCNJ6 2924/4885KCNJ5 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.